Cytosorbents CorporationCTSONASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +11.08% | +24.52% | -2.92% | +8.76% | +10.13% |
| Gross Profit Growth | -1.01% | +87.90% | -9.69% | +4.78% | +48.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +23.32% | +22.53% | +11.92% | +15.29% | +14.67% |
| Weighted Average Shares Diluted Growth | +22.71% | +22.53% | +11.92% | +23.68% | +15.24% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +7.35% | +20.84% | +13.38% | -1.02% | +11.98% |
| Inventory Growth | +9.09% | -25.74% | -19.26% | -14.06% | +23.22% |
| Asset Growth | +0.48% | -11.06% | +7.88% | -10.18% | -4.30% |
| Book Value per Share Growth | -43.06% | -61.05% | -31.35% | -39.95% | -39.49% |
| Debt Growth | +48.58% | +46.85% | +53.18% | +1.09% | +1.23% |
| R&D Expense Growth | -50.62% | -68.30% | -25.99% | -16.92% | -50.41% |
| SG&A Expenses Growth | -15.00% | -9.79% | -100.00% | -100.00% | +10.01% |